Logo

CSBR

Champions Oncology, Inc.

CSBR

Champions Oncology, Inc. • NASDAQ
$6.54 ▲ 0.62% (+0.04)
Market Cap $90.15 M
52w High $11.99
52w Low $4.11
Dividend Yield 0%
P/E 31.14
Volume 2.13K
Outstanding Shares 13.79M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q1-2026 $0 ▼ $6.527M ▼ $-466K ▲ 0% ▲ $-0.03 ▲ $-527K ▲
Q4-2025 $12.355M ▼ $7.091M ▲ $-1.834M ▼ -14.844% ▼ $-0.13 ▼ $-1.32M ▼
Q3-2025 $17.039M ▲ $5.923M ▲ $4.495M ▲ 26.381% ▲ $0.33 ▲ $4.916M ▲
Q2-2025 $13.489M ▼ $5.329M ▼ $728K ▼ 5.397% ▼ $0.054 ▼ $1.131M ▼
Q1-2025 $14.061M $5.66M $1.313M 9.338% $0.097 $1.778M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q1-2026 $10.325M ▲ $30.546M ▼ $27.008M ▼ $3.508M ▼
Q4-2025 $9.785M ▲ $32.344M ▲ $28.572M ▲ $3.772M ▼
Q3-2025 $3.202M ▲ $30.627M ▲ $25.158M ▲ $5.469M ▲
Q2-2025 $2.754M ▼ $25.24M ▲ $24.559M ▼ $681K ▲
Q1-2025 $2.892M $24.933M $25.265M $-332K

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q1-2026 $-466K ▲ $600K ▼ $-46K ▲ $-14K ▲ $540K ▼ $554K ▼
Q4-2025 $-1.835M ▼ $6.868M ▲ $-253K ▼ $-32K ▼ $6.583M ▲ $6.615M ▲
Q3-2025 $4.495M ▲ $490K ▲ $-42K ▲ $0 ▼ $448K ▲ $448K ▲
Q2-2025 $728K ▼ $-283K ▼ $-94K ▼ $239K ▲ $-138K ▼ $-377K ▼
Q1-2025 $1.313M $311K $0 $-37K $274K $311K

Revenue by Products

Product Q2-2025Q3-2025Q4-2025Q1-2026
Pharmacology Services
Pharmacology Services
 $10.00M ▲$10.00M ▲$10.00M ▲$10.00M ▲
Product and Service Other
Product and Service Other
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has been slowly but steadily increasing, which suggests the core business is gaining some traction. Profitability is hovering around break-even, with a recent year of noticeable loss followed by a return to roughly flat or slightly positive results. Gross margins appear reasonably healthy for a specialized service business, but the company has limited room for error given its small scale. Overall, the income statement shows a business that is stabilizing but still vulnerable to swings in demand or spending decisions.

Balance Sheet

Balance Sheet The company operates with a relatively small asset base and a modest cash cushion, reflecting its niche size. Debt levels are present but not excessive in absolute terms, though they matter more because shareholder equity is quite thin. Very low equity signals that past losses have eroded the balance sheet and leave less of a buffer if results weaken again. In simple terms, the financial foundation is adequate for a small, steady business but not especially robust, which increases sensitivity to any downturns.

Cash Flow

Cash Flow Cash generation from operations tends to hover around break-even, with some years slightly positive and at least one year noticeably negative. Capital spending is very light, so free cash flow largely depends on how well the core business performs in any given year. This pattern points to a company that can sometimes fund itself but may need external capital or tight cost control to support bigger growth or new initiatives. Overall, cash flow is not yet consistently strong or predictable, which adds to financial risk.

Competitive Edge

Competitive Edge Champions Oncology occupies a focused niche in preclinical oncology, built around its large bank of patient-derived tumor models and deep clinical data. This specialized offering, combined with its Lumin data and analytics platform, creates a differentiated value proposition versus more generalist contract research organizations. Long-term relationships with cancer centers and drug developers further entrench its role as a partner rather than a simple vendor. However, it still competes with much larger global players, so maintaining its edge depends on continuing to innovate and staying ahead in data quality and scientific expertise.

Innovation and R&D

Innovation and R&D Innovation is at the heart of the business, with proprietary TumorGraft models, 3D organoid platforms, and the Lumin bioinformatics system forming a tightly integrated technology stack. The company is increasingly treating its dataset as a product, pushing into data subscriptions and analytics, which could create higher-margin, recurring revenue over time. It is also exploring internal drug discovery and advanced therapy support, using AI and multi-omic data to identify new targets and biomarkers. These initiatives offer meaningful upside but come with long timelines, scientific uncertainty, and a clear need for sustained investment and funding discipline.

Summary

Champions Oncology is a small, specialized player in cancer research services and data, showing gradual revenue growth and results that hover around break-even. Its scientific and data assets provide a real competitive edge in a very technical niche, and its platforms position it well for trends in personalized and data-driven oncology. At the same time, the balance sheet is thin, cash flow is not yet consistently strong, and the business remains sensitive to shifts in demand and spending. The long-term story hinges on successfully monetizing its unique datasets and platforms, while carefully managing financial risk as it pursues more ambitious innovation and potential drug discovery efforts.

NEWS

September 15, 2025 · 4:50 PM UTC

CORRECTION: Champions Oncology Reports Quarterly Revenue of $14.0 Million

Read more

September 10, 2025 · 4:30 PM UTC

Champions Oncology to Announce First Quarter Financial Results on Monday, September 15, 2025

Read more